10145729Automated Microscopy system for single cell raman spectroscopy for Pathogen IDClosedCollaborative R&DInnovate UKRamanomics, an Oxford-based startup, is developing a groundbreaking diagnostic platform set to revolutionize the detection of blood infections. By harnessing advanced single-cell Raman spectroscopy combined with cutting-edge Machine Learning algorithms, the technology enables rapid and accurate identification of pathogens directly from blood samples---eliminating the need for traditional culturing methods. Traditional diagnostics for blood infections often rely on culturing, a time-consuming process that can take several days and delay critical treatment decisions. Ramanomics' innovative approach reduces the time to results from days to hours, which is vital for life-threatening conditions like septic shock and bacterial meningitis. Faster diagnosis means timely, targeted treatment, potentially saving lives and improving patient outcomes. The company's proprietary technology involves an automated Raman microscope capable of detecting a wide array of pathogens at the single-cell level. By integrating sophisticated Machine Learning models, the platform enhances the accuracy and speed of pathogen identification. Designed to be user-friendly and cost-effective, the system aims to make advanced diagnostics more accessible across various healthcare settings. Ramanomics is committed to advancing global healthcare by making rapid diagnostics attainable not just in well-resourced hospitals but also in lower-income regions. The technology holds the promise of significant cost savings for healthcare systems by reducing hospital stays and improving antibiotic stewardship, thereby combating the rise of antimicrobial resistance. The project includes extensive validation studies using human blood samples to ensure the performance and reliability. Collaborations with healthcare institutions will facilitate the integration of the platform into existing medical workflows. Through this innovative endeavor, Ramanomics aspires to become a leader in rapid diagnostics, contributing to better healthcare outcomes worldwide. By bridging the gap between cutting-edge research and practical clinical application, the company aims to make a lasting impact on patient care and the global fight against infectious diseases.